Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak
This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | COVID-19 | Laboratory Medicine | Outbreaks | Pandemics | Temodar